Serotype-specific anti-dengue virus NS1 mouse antibodies cross-react with prM and are potentially involved in virus production

Viral Immunology

Volumn 26, Issue 4, 2013, Pages 250-258

  Masrinoul, Promsin ^a,b   Omokoko, Magot Diata ^a   Pambudi, Sabar ^a   Ikuta, Kazuyoshi ^a   Kurosu, Takeshi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 4; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPRECIPITATION; MONOCYTE; MOUSE; NONHUMAN; SEROTYPE; SUCKLING; SURVIVAL RATE; VIRUS NEUTRALIZATION;

AEDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CRICETINAE; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84882400783     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0102     Document Type: Article

References (45)

1. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, and Flamand M. Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol 2002;40:376-381.
2. Avirutnan P, Punyadee N, Noisakran S, et al. 2006. Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006;193:1078-1088.
3. Brandt WE, Chiewslip D, Harris DL, and Russell PK. Partial purification and characterization of a dengue virus soluble complement-fixing antigen. J Immunol 1970;105:1565-1568.
4. Cheng HJ, Lei HY, Lin CF, et al. Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Mol Immunol 2009;47:398-406.
5. Chung KM, Liszewski MK, Nybakken G, et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci USA 2006;103:19111-19116.
6. da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nun ez NV, et al. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype PLoS One 2012;7:e29957.
7. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012; 109:7439-7444.
8. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Crossreacting antibodies enhance dengue virus infection in humans. Science 2010;328:745-748. Erratum in: Science 2010; 329:142.
9. Dowd KA, and Pierson TC. 2011. Antibody-mediated neutralization of flaviviruses: A reductionist view. Virology 2011;411:306-315.
10. Falconar AK. 1997. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997;142:897-916.
11. Falconar AK. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: Implications for pathogenesis and vaccines. Clin Vaccine Immunol 2008; 15:549-561.
12. Falconar AK. The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal outbred mice resulting in lethal multi-organ disease. PLOS One 2011;6:1-14.
13. Falgout B, Bray M, Schlesinger JJ, and Lai CJ. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol 1990;64: 4356-4363.
14. Falkler WA Jr, Diwan AR, and Halstead SB. Human antibody to dengue soluble complement-fixing (SCF) antigens. J Immunol 1973;111:1804-1809.
15. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 2002;33: 330-342.
16. Guzman MG, and Vazquez S. The complexity of antibodydependent enhancement of dengue virus infection. Viruses 2010;2:2649-2662.
17. Halstead SB, Chow JS, and Marchette NJ. Immunological enhancement of dengue virus replication. Nat New Biol 1973;243:24-26.
18. Henchal EA, Henchal LS, and Schlesinger JJ. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol 1988;69:2101-2107.
19. Hu D, Di B, Ding X, et al. Kinetics of non-structural protein 1, IgM and IgG antibodies in dengue type 1 primary infection. Virol J 2011;8:47.
20. Huang JL, Huang JH, Shyu RH, et al. High-level expression of recombinant dengue viral NS-1 protein and its potential use as a diagnostic antigen. J Med Virol 2001;65:553-560.
21. Junjhon J, Edwards TJ, Utaipat U, et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol 2010;84:8353-8358.
22. Kaufman BM, Summers PL, Dubois DR, et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1989; 41:576-580.
23. Kouri GP, Guzman MG, Bravo JR, and Triana C. Dengue haemorrhagic fever/dengue shock syndrome: Lessons from the Cuban epidemic, 1981. Bull World Health Organ 1989; 67:375-380.
24. Kuno G, Vorndam AV, Gubler DJ, and Gomez I. Study of anti-dengue NS1 antibody by western blot. J Med Virol 1990;32:102-108.
25. Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008;82:6631-6643.
26. Li L, Lok SM, Yu IM, et al. The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science 2008;319:1830-1834.
27. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002;186:1165-1168.
28. Lin CF, Chiu SC, Hsiao YL, et al Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein J Immunol 2005;174:395-403.
29. Masrinoul P, Omokoko MD, Pambudi S, Limkittikul K, Ikuta K, and Kurosu T. Highly conserved region 141-168 of the NS1 protein is a new common epitope region of dengue virus. Jpn J Infect Dis 2011;64:109-115.
30. Meyer K, Banerjee A, Frey SE, Belshe RB, and Ray R. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One 2011;6: e23699.
31. Nakayama E, Tomabechi D, Matsuno K, Kishida N, Yoshida R, Feldmann H, and Takada A. Antibody-dependent enhancement of Marburg virus infection. J Infect Dis 2011;204: S978-985.
32. Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, et al. A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J Virol 2011;85:11800-11808.
33. Rothman AL. Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011;11:532-543.
34. Schlesinger JJ, Brandriss MW, and Walsh EE. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol. 1985;135: 2805-2809.
35. Schlesinger JJ, and Brandriss MW. Growth of 17D yellow fever virus in a macrophage-like cell line, U937: Role of Fc and viral receptors in antibody-mediated infection. J Immunol 1991;127:659-665.
36. Schlesinger JJ, Brandriss MW, and Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 1987;68:853-857.
37. Setthapramote C, Sasaki T, Puiprom O, et al. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection. Biochem Biophys Res Commun 2012; 423:867-872.
38. Shu PY, Chang SF, Kuo YC, et al. Development of groupand serotype-specific one-step SYBR green I-based real-time reverse transcription-PCR assay for dengue virus. J Clin Microbiol 2003;41:2408-2416.
39. Tirado SM, and Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003;16: 69-86.
40. Valdes K, Alvarez M, Pupo M, Vazquez S, Rodr?guez R, and Guzman MG. Human dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol 2000; 7:856-857.
41. Wahala WM, and Silva AM. The human antibody response to dengue virus infection. Viruses 2011;3:2374-2395.
42. Whitehorn J, and Simmons CP. The pathogenesis of dengue. Vaccine 2011;29:7221-7228.
43. World Health Organization. Dengue and severe dengue fact sheet. 2012. www.who.int/mediacentre/factsheets/fs117/ en/.
44. Young PR, Hilditch PA, Bletchly C, and Halloran W. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol 2000;38:1053-1057.
45. Zhang YM, Hayes EP, McCarty TC, et al. Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J Virol 1988;62: 3027-3031.